AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/14/21

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in two upcoming investor conferences: RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at ...

– Company-sponsored program seeks proposals to help patients in the U.S. make informed health choices and support underserved populations with these conditions – – Submission process opens on World Lupus Day, Monday May 10, deadline to submit proposa...

The Lancet has published the results of Aurinia Pharmaceuticals' (AUPH) Phase 3 AURORA 1 study evaluating Lupkunis (voclosporin) in adults with lupus nephritis ((LN)). AURORA 1 met its primary endpoint, achieving statistically superior complete renal response rates of 41% in the Lupkynis...

Study results demonstrate that LUPKYNIS in combination with typical standard of care (SoC) led to statistically superior complete renal response rates compared to treatment with SoC alone Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or ...

Aurinia Pharmaceuticals ([[AUPH]] -18.2%) has plunged after the company’s Q1 financials came below expectations.Weighing on the results, Cantor Fitzgerald has maintained the overweight rating and the price target of $34.00 per share which indicates an upside of ~175.5% to the...

Gainers: InnSuites Hospitality Trust (IHT) +95%.Regional Health Properties (RHE) +30%.Cooper-Standard (CPS) +25%.MoneyGram International (MGI) +23%.Epizyme (EPZM) +21%.The L.S. Starrett (SCX) +21%.Clene (CLNN) +20%.Yield10 Bioscience (YTEN) +20%.Phio Pharmaceuticals (PHIO) +19%.Core...

Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aur...

ChemoCentryx (CCXI) -49% after FDA panel split 9-9 on efficacy for Chemocentryx's vasculitis candidate avacopan and reports outcome of FDA’s expert panel meeting on avacopan.Orphazyme  (ORPH) -28% after arimoclomol flunks late-stage amyotrophic lateral sclerosi...

Aurinia Pharmaceuticals (AUPH) down 20% after-hours after announcing financial results for the first quarter ended March 31, 2021.Revenues were $0.9M and $30K for Q1 2021 and 2020, respectively. The increase was the result of the commercial sales of Lupkynis, which began in January ...

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2021 Results Earnings Conference Call May 06, 2021, 5:00 pm ET Company Participants Glenn Schulman - Senior Vice President, Corporate Communications and Investor Relations Peter Greenleaf - Chief Executive Officer, Director Max Colao - Chief Commercial O...